Radius Health Inc. buy tamam
Start price
30.01.18
/
50%
€35.46
Target price
04.11.21
€21.41
Performance (%)
-47.87%
End price
05.11.21
€18.49
Summary
This prediction ended on 05.11.21 with a price of €18.49. Massive losses of -47.87% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Radius Health Inc. | - | - | - | - |
| iShares Core DAX® | 1.051% | -1.833% | 12.822% | 15.392% |
| iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% | 42.396% |
| iShares Nikkei 225® | -1.778% | -8.115% | 16.092% | 0.891% |
| iShares S&P 500 | 0.002% | -2.226% | 28.387% | 41.095% |
Comments by tamam for this prediction
In the thread Radius Health Inc. diskutieren
Radius Health could Advance 50% With Osteoporosis Treatment
Morgan Stanley analyst initiated coverage of the company with an Overweight rating and a $57 price target.
Radius is set to launch Tymlos, a bone builder for women with osteoporosis, but despite Eli Lilly's presence in the market with Forteo, which fetched the company $1 billion in sales and is exposed to generic competition in 2019, the analyst said Tymlos' pricing is 40 percent lower than Forteo's — and
convenience could help it grab share.
Radius Health is a Conviction Buy!
Kursziel geändert auf 41,414
Kursziel geändert auf 21,414
In the thread Trading Radius Health Inc.
Die von tamam gewählte maximale Laufzeit wurde überschritten